Nasdaq:SBFM
Sunshine Biopharma Inc.
Clinical-stage biopharmaceutical company advancing innovative oncology and immunology therapies through proprietary platforms and strategic partnerships.
Key Metrics
Investment Thesis
Bull Case
Investors might consider SBFM attractive due to its high-growth revenue trajectory, which more than doubled from $4.3M in 2022 to $34.9M in 2024, driven by expanding licensing partnerships and successful clinical milestones, offering significant upside potential if upcoming drug candidates achieve regulatory approval, while the company's strong balance sheet relative to its asset base provides a buffer against market volatility.
Bear Case
The stock carries substantial risk given the persistent net losses of $5.1M in 2024 and a growing retained earnings deficit of $69.0M, suggesting the business model requires continuous external capital injections which may dilute existing shareholders or exhaust liquidity if funding markets tighten, alongside the inherent volatility of clinical-stage biotech where a single failed trial could render the current valuation obsolete.
About Sunshine Biopharma Inc.
Sunshine Biopharma Inc. (SBFM) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs in oncology and immunology markets. The company leverages its proprietary technology platform to generate revenue through licensing agreements, collaboration partnerships, and potential commercialization of novel drug candidates. SBFM operates within the competitive landscape of early-stage biotech firms, utilizing a lean operational model to advance its pipeline from discovery to clinical trials.
Analysis
Management Discussion
In 2024, SBFM reported a net loss of $5.1M against total revenue of $34.9M, representing a notable improvement from the $26.7M loss recorded in 2022 and a slight increase in losses from 2023's $4.5M, indicating stabilizing operational costs despite growing R&D expenditures of roughly $1.0M. While the company successfully managed its current liabilities at $6.3M against $26.0M in current assets, ending cash reserves decreased to $9.7M from a beginning balance of $16.3M, reflecting net cash outflows from operations and investing activities that require continued capital raising efforts.
Industry Overview
The biotechnology and pharmaceutical industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles before products can reach market, yet it offers massive growth potential for companies that successfully navigate clinical trials to bring novel therapies to patients with unmet needs like cancer and autoimmune diseases.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $4.3M | $24.1M | $34.9M |
| Cost of Revenue | $2.6M | $15.8M | $24.2M |
| Gross Profit | $1.7M | $8.3M | $10.7M |
| Operating Expenses | $28.7M | $13.1M | $16.5M |
| Operating Income | $-27.0M | $-4.8M | $-5.8M |
| R&D | $811.9K | $1.9M | $933.9K |
| G&A | $28.7M | $13.1M | $16.5M |
| D&A | $25.2K | $149.1K | $223.5K |
| Depreciation | — | $110.7K | $146.5K |
| Amortization | — | — | $77.0K |
| Other OpEx | $-811.9K | $-1.9M | $-933.9K |
| Non-Operating Income | $489.6K | $674.4K | $443.1K |
| Interest Expense | $39.4K | $137.3K | — |
| Pre-Tax Income | $-26.5M | $-4.1M | $-5.4M |
| Income Tax | $233.3K | $395.2K | $-234.9K |
| Continuing Ops | $-26.7M | $-4.5M | $-5.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-26.7M | $-4.5M | $-5.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-26.7M | $-4.5M | $-5.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $27.3M | $24.9M | $26.0M |
| Cash & Equivalents | $21.8M | — | — |
| Accounts Receivable | $1.9M | $2.6M | $3.9M |
| Inventory | $3.3M | $5.7M | $11.3M |
| Other Current Assets | $283.8K | $16.6M | $10.8M |
| Long-Term Assets | $1.9M | $2.5M | $4.6M |
| PP&E (Net) | $394.2K | $365.9K | $546.1K |
| Intangibles | $776.9K | $1.4M | $3.0M |
| Goodwill | — | $0 | $0 |
| Operating Leases | $760.4K | $646.8K | $936.0K |
| Other LT Assets | $0 | $0 | $92.2K |
| Total Assets | $29.2M | $27.3M | $30.6M |
| Current Liabilities | $6.9M | $5.6M | $6.3M |
| Accounts Payable | $2.8M | $2.6M | $5.5M |
| Current Leases | $123.0K | $118.7K | $207.8K |
| Taxes Payable | $373.2K | $299.9K | $268.3K |
| Other Current Liab | $3.6M | $2.5M | $295.8K |
| Long-Term Liabilities | $685.3K | $587.8K | $744.7K |
| LT Operating Leases | $642.2K | $539.0K | $744.7K |
| Other LT Liab | $43.0K | $48.7K | $0 |
| Total Liabilities | $7.6M | $6.1M | $7.1M |
| Shareholders' Equity | $21.6M | $21.2M | $23.5M |
| Paid-In Capital | $80.8M | $84.4M | $93.4M |
| Retained Earnings | $-59.4M | $-63.9M | $-69.0M |
| AOCI | $161.8K | $696.1K | $-830.0K |
| Total L&E | $29.2M | $27.3M | $30.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-26.7M | $-4.5M | $-5.1M |
| Non-Cash Adjustments | $17.5M | $-5.8M | $-19.1M |
| Working Capital Changes | $4.0M | $1.5M | $11.7M |
| Cash from Operations | $-5.2M | $-8.8M | $-12.5M |
| Capital Expenditures | $194.0K | $82.3K | $1.7M |
| Cash from Investing | $-14.6M | $-656.1K | $-2.3M |
| Share Buybacks | — | — | $3.1M |
| Cash from Financing | $39.5M | $3.4M | $9.3M |
| FX Effect | $-1.1K | $-62.7K | $0 |
| Net Change in Cash | $19.6M | $-6.0M | $-5.6M |
| Beginning Cash | $2.0M | $21.8M | $16.3M |
| Ending Cash | $21.8M | $16.3M | $9.7M |
Frequently Asked Questions
How does Sunshine Biopharma Inc. make money?
The company's revenue streams primarily derive from collaboration agreements with major pharmaceutical partners for the development of novel cell therapies, licensing fees generated from intellectual property rights, and milestone payments upon the achievement of specific clinical or regulatory endpoints in its pipeline assets.
What are the main risks for SBFM?
The company faces significant execution risk as it relies heavily on external funding sources to sustain operations given its negative operating cash flow of $12.5M in 2024, regulatory uncertainty surrounding the approval of novel cell therapy candidates which could delay revenue recognition, and the potential for clinical trial failures or adverse safety events that would materially impact its valuation, alongside patent expiration risks once current agreements conclude.
What is SBFM's competitive advantage?
SBFM possesses a differentiated proprietary technology platform that reduces development timelines and costs compared to traditional asset discovery methods, fostering strong relationships with top-tier academic institutions for high-quality compound sourcing, and maintaining a streamlined organizational structure that maximizes capital efficiency during the pre-commercialization phase.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.